HESI OFFICIAL REPRESENTATIVES ASSEMBLY MEETING

Tuesday, 9 June, 2015
1:00 pm to 1:45 pm

Washington Ballroom
Westin Georgetown Hotel
Washington, DC 20037

AGENDA

Session led by Laurie Hanson, DVM, PhD, HESI President

1:00 Welcome
1:05 Business and ‘Board News’ Update
1:25 Trustee Elections – Requires Motion and Vote
1:35 Other Business/Discussion
1:45 Adjourn
HESI OFFICIAL REPRESENTATIVES ASSEMBLY MEETING

Tuesday, 9 June 2015
1:00 pm to 1:45 pm

Washington Ballroom
Westin Georgetown Hotel
Washington, DC 20037

ANTICIPATED ATTENDEES

Dr. Mudher Albassam Hoffmann-La Roche, Inc.
Dr. Herman Autrup University of Aarhus
Dr. Marcy Banton LyondellBasell
Dr. Norman Barlow Janssen, Johnson & Johnson
Dr. Scott Belanger The Procter & Gamble Company
Mrs. Mariela Berezovsky ILSI Brasil
Mr. Oscar Bermudez HESI
Dr. Brian Berridge GlaxoSmithKline
Ms. Beth-Ellen Berry ILSI
Dr. David Brewster Vertex Pharmaceuticals
Prof. Alan Boobis Imperial College London
Dr. Connie Chen ILSI Health and Environmental Sciences Institute
Dr. Samuel Cohen University of Nebraska Medical Center
Dr. Jon Cook Pfizer Inc
Dr. Myrtle Davis National Cancer Institute, NIH
Mr. Philippe Detilleux Sanofi
Dr. Dennis Devlin Exxon Mobil Corporation
Dr. Michelle Embry HESI
Ms. Brianna Farr HESI
Ms. Teyent Getaneh HESI
Ms. Melissa Gilden HESI
Dr. Andrew Glickman Chevron Corporation
Dr. Daniel Goldstein Monsanto
Dr. Michael Graziano Bristol-Myers Squibb Company
Dr. Patrick Guiney University of Wisconsin
Dr. Peggy Guzzie-Peck Janssen, Johnson & Johnson
Dr. Laurie Hanson Pfizer, Inc.
Dr. Ernie Harpur Newcastle University
Dr. Charles Hastings BASF Corporation
Dr. Julia Hui Celgene Corporation
Dr. Robert Johnson Novartis Pharmaceuticals
Prof. James Klaunig Indiana University
Dr. Serrine Lau University of Arizona
Dr. Lois Lehman-McKeeman Discovery Toxicology, Bristol-Myers Squibb Company
Prof. Paul Lioy Rutgers University - RBHS-RWJMS
Dr. José Manautou University of Connecticut
Dr. Don Marsh Merck Research Laboratories
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Charlene McQueen</td>
<td>US Environmental Protection Agency</td>
</tr>
<tr>
<td>Dr. Gary Minsavage</td>
<td>ExxonMobil Biomedical Sciences, Inc.</td>
</tr>
<tr>
<td>Prof. Angelo Moretto</td>
<td>University of Milan, Italy</td>
</tr>
<tr>
<td>Dr. Raegan O'Lon</td>
<td>HESI</td>
</tr>
<tr>
<td>Dr. Stan Parish</td>
<td>HESI</td>
</tr>
<tr>
<td>Dr. Timothy Pastoor</td>
<td>Syngenta</td>
</tr>
<tr>
<td>Mrs. Syril Pettit</td>
<td>ILSI Health and Environmental Sciences Institute</td>
</tr>
<tr>
<td>Prof. Martin Philbert</td>
<td>Univ. of Michigan School of Public Health</td>
</tr>
<tr>
<td>Mrs. Jennifer Pierson</td>
<td>HESI</td>
</tr>
<tr>
<td>Dr. Robert Rickard</td>
<td>DuPont</td>
</tr>
<tr>
<td>Prof. Ruth Roberts</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Dr. Craig Rowlands</td>
<td>The Dow Chemical Company</td>
</tr>
<tr>
<td>Dr. Keiichiro Sato</td>
<td>Takeda Pharmaceutical Company</td>
</tr>
<tr>
<td>Prof. Lewis Smith</td>
<td>University of Leicester</td>
</tr>
<tr>
<td>Dr. James Stevens</td>
<td>Lilly Research Laboratories</td>
</tr>
<tr>
<td>Shawn Sullivan, Esq.</td>
<td>ILSI</td>
</tr>
<tr>
<td>Ms. Ayako Takei</td>
<td>ICaRuS Japan Limited</td>
</tr>
<tr>
<td>Dr. Jennifer Tanir</td>
<td>HESI</td>
</tr>
<tr>
<td>Dr. Akira Unami</td>
<td>Astellas Pharma Inc.</td>
</tr>
<tr>
<td>Dr. Martin van den Berg</td>
<td>Utrecht University, Institute for Risk Assessment Sciences</td>
</tr>
</tbody>
</table>
New Nominees
Jerry S.H. Lee, PhD, Deputy Director, Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health

Re-Nominees
Herman N. Autrup, PhD, University of Aarhus
Sonja Beken, PhD, Federal Agency Medicines and Health Products
Brian R. Berridge, DVM, PhD, DACVP, GlaxoSmithKline
Alan R. Boobis, OBE, PhD, Imperial College London
Samuel M. Cohen, MD, PhD, University of Nebraska Medical Center
Myrtle Davis, DVM, PhD, Chief, National Cancer Institute
Shoji Fukushima, MD, PhD, Japan Bioassay Research Center
Laurie A. Hanson, DVM, PhD, DABT, Pfizer Inc.
Lois Lehman-McKeeman, PhD, Bristol-Myers Squibb
Lewis L. Smith, BSc, PhD, FRCPath, University of Leicester
Dr. rer. nat. Bennard van Ravenzwaay, BASF SE

2014-2015 Board of Trustees
Herman N. Autrup, PhD, University of Aarhus
Sonja Beken, PhD, Federal Agency Medicines and Health Products
Scott E. Belanger, PhD, The Procter & Gamble Company
Brian R. Berridge, DVM, PhD, DACVP, GlaxoSmithKline
Alan R. Boobis, OBE, PhD, Imperial College London
David Brewster, PhD, DABT, Vertex Pharmaceuticals Incorporated
Samuel M. Cohen, MD, PhD, University of Nebraska Medical Center
Myrtle Davis, DVM, PhD, National Cancer Institute
Dennis J. Devlin, PhD, Exxon Mobil Corporation
David L. Eaton, PhD, University of Washington
Shoji Fukushima, MD, PhD, Japan Bioassay Research Center
Patrick D. Guiney, PhD, University of Wisconsin
Peggy J. Guzzie-Peck, MS, PhD, DABT, Janssen Pharma R&D, LLC
Laurie A. Hanson, DVM, PhD, DABT, Pfizer Inc.
Ernie Harpur, BSc, PhD, ATS, FBTS, Newcastle University
Serrine S. Lau, PhD, University of Arizona
Lois Lehman-McKeeman, PhD, Bristol-Myers Squibb Company
Charlene A. McQueen, PhD, ATS, Research Triangle Park, NC
Angelo Moretto, MD, PhD, University of Milan
Timothy P. Pastoor, PhD, DABT, Syngenta Crop Protection, Inc.
Martin A. Philbert, PhD, University of Michigan
Stefan J. Platz, DVM, PhD, DABT, AstraZeneca Pharmaceuticals LP
J. Craig Rowlands, PhD, DABT, The Dow Chemical Company
Atsushi Sambuissho, DVM, PhD, Daiichi Sankyo Co., Ltd.
Keiichiro Sato, DVM, PhD, DJSOT, DABT, Takeda Pharmaceutical Company Limited
Lewis L. Smith, BSc, PhD, FRCPath, University of Leicester
James L. Stevens, PhD, Eli Lilly and Company
Martin van den Berg, PhD, Utrecht University
Jan Willem van der Laan, PhD, Medicines Evaluation Board
Bennard van Ravenzwaay, Dr. rer. nat., BASF SE
Kendall B. Wallace, PhD, University of Minnesota
2015-2016 Proposed Board of Trustees
Herman N. Atrup, PhD, University of Aarhus
Sonja Beken, PhD, Federal Agency Medicines and Health Products
Scott E. Belanger, PhD, The Procter & Gamble Company
Brian R. Berridge, DVM, PhD, DACVP, GlaxoSmithKline
Alan R. Boobis, OBE, PhD, Imperial College London
David Brewster, PhD, DABT, Vertex Pharmaceuticals Incorporated
Samuel M. Cohen, MD, PhD, University of Nebraska Medical Center
Myrtle Davis, DVM, PhD, National Cancer Institute
Dennis J. Devlin, PhD, Exxon Mobil Corporation
Shoji Fukushima, MD, PhD, Japan Bioassay Research Center
Patrick D. Guiney, PhD, University of Wisconsin
Peggy J. Guzzie-Peck, MS, PhD, DABT, Janssen Pharma R&D, LLC
Laurie A. Hanson, DVM, PhD, DABT, Pfizer Inc.
Ernie Harpur, BSc, PhD, ATS, FBTS, Newcastle University
Serrine S. Lau, PhD, University of Arizona
Jerry S.H. Lee, PhD, National Cancer Institute
Lois Lehman-McKeeman, PhD, Bristol-Myers Squibb Company
Charlene A. McQueen, PhD, ATS, Research Triangle Park, NC
Angelo Moretto, MD, PhD, University of Milan
Timothy P. Pastoor, PhD, DABT, Syngenta Crop Protection, Inc.
Martin A. Philbert, PhD, University of Michigan
Stefan J. Platz, DVM, PhD, DABT, AstraZeneca Pharmaceuticals LP
J. Craig Rowlands, PhD, DABT, The Dow Chemical Company
Atsushi Sambuissho, DVM, PhD, Daiichi Sankyo Co., Ltd.
Keiichi Sato, DVM, PhD, DJSOT, DABT, Takeda Pharmaceutical Company Limited
Lewis L. Smith, BSc, PhD, FRCPath, University of Leicester
James L. Stevens, PhD, Eli Lilly and Company
Martin van den Berg, PhD, Utrecht University
Jan Willem van der Laan, PhD, Medicines Evaluation Board
Bennard van Ravenzwaay, Dr. rer. nat., BASF SE
Kendall B. Wallace, PhD, University of Minnesota
Autrup, Herman Nybro, PhD

Prof. Herman Autrup is past-President, EUROTOX, president IUTOX, and holds positions as Professor of Environmental Medicine at the University of Aarhus in Århus, Denmark, Adjunct Professor at the Chulabhorn Graduate Institute in Bangkok, Thailand, and Extra-ordinary Professor, School of Public Health, University of Pretoria, South Africa. He received his Ph.D. in Experimental Pathology from the University of Nairobi in 1995 and a Candidatus Scientiarum in Organic Chemistry from the University of Copenhagen in 1971. He is member of the Danish Academy of Technical Sciences and a fellow of ATS (board member). His research interest is molecular epidemiology, with focus on molecular markers of susceptibility and exposure, air pollution. He is currently coordinating an interdisciplinary project on the safety of nanoparticles. Prof. Autrup is a member of several editorial boards including Tox Sci, and is invited reviewer for 15 different journals in the area of environmental toxicology and nanotoxicology, and is often invited to give lectures at international meetings and international research institutes. He has authored more than 200 publications in peer-reviewed journals and more than 50 publications in books and meeting proceedings and is the co-editor of 6 books. He received the European Environmental Mutagen Society’ Fritz Sobel award in 2006 for his contribution in the area of carcinogen-DNA adducts, the Princess Chulabhorn of Thailand’s Gold Medal Award in 2007, EUROTOX Merit award in 2013 and the SOT Educational award in 2014. He is a member of the Society of Toxicology (USA), and the European Society of Toxicology (honorary member).

Beken, Sonja, PhD

Sonja Beken obtained her Master in Biological Sciences at the Vrije Universiteit Brussel (VUB), Belgium, holds a PhD in Pharmaceutical Sciences (VUB) and a Master in Applied Toxicology from the University of Surrey, UK. Sonja Beken is the Head of the Unit of non-clinical evaluators within the Belgian Federal Agency for Medicines and Health Products (FAMHP). This Unit is responsible for the evaluation of non-clinical data (pharmacology, pharmacokinetics and toxicology) submitted to support all phases of the life cycle of drug development (e.g. marketing authorization applications, clinical trial applications, EU and national scientific advice, paediatric investigation plans, etc). She is Vice-Chair of the Safety Working Party (SWP), Chair of the CVMP/CHMP Joint Ad Hoc Expert Group on 3R’s (JEG 3Rs), both at the European Medicines Agency (EMA) and she is Group Leader of the Informal SS(R3) Working Group at the level of the International Conference on Harmonisation (ICH). In June 2014 she was elected as Member of the Board Of Trustees of HESI (Health and Environmental Sciences Institute, US). Her main areas of expertise relate to regulatory science, non-clinical drug development, (in vitro) toxicology and metabolism as well as alternative models to animal experiments (3Rs).

Berridge, Brian R., DVM, PhD, DACVP

Brian Berridge is Director and Head of WW Animal Research Strategy in the Office of Animal Welfare, Ethics and Strategy at GlaxoSmithKline. In that position he leads efforts to advance the scientific impact of animal and non-animal modeling in support of pharmaceutical development. He has held previous positions as a Director of Regulatory & Discovery Pathology at GSK and Principal Research Pathologist at Eli Lilly & Company. Brian is an Oklahoma State University-trained veterinarian with residency and PhD training from Texas A&M University. He is a Diplomate of the American College of Veterinary Pathologists and holds an adjunct Associate Professor position in the Department of Population Health and Pathobiology at North Carolina State University. He additionally teaches cardiovascular toxicology at the University of North Carolina. He is a member of the Executive Board and Board of Trustees for the ILSI Health and Environmental Sciences Institute where he also co-chairs the HESI Cardiac Safety Technical Committee, the Integrated CV Strategies Working Group, and the Translational Preclinical Imaging Technical Committee. Brian also chairs an international effort to harmonize cardiovascular nomenclature in regulatory toxicologic pathology and a CV Specialty Interest Group within the Society of Toxicologic Pathologists.
Boobis, Alan R., OBE, PhD

Alan Boobis is currently Professor of Biochemical Pharmacology and Director of the Public Health England Toxicology Unit at Imperial College London. He has been a member of Imperial College London for almost 40 years. His main research interests lie in mechanistic toxicology, drug metabolism, mode of action and chemical risk assessment. He has published around 230 original research papers (H-factor 63). He is a member of several national and international advisory committees, the Committee on Toxicity (chair), the WHO Study Group on Tobacco Product Regulation (TobReg), JECFA (veterinary residues – co-chair) and JMPR (alternating co-chair). He has been a member of the UK Advisory Committee on Pesticides, Committee on Carcinogenicity, the EFSA CONTAM Panel and the EFSA PPR Panel. He is a member and a past chairman of the Board of Trustees of ILSI (International Life Sciences Institute) HESI, vice-president of ILSI Europe and chair of ILSI. He is involved in several HESI, ILSI RF and ILSI Europe projects. Awards include fellowship of the Society of Biology and the British Toxicology Society, the BTS John Barnes Prize Lectureship, honorary membership and Merit Award of EUROTOX, the Royal Society of Chemistry Toxicology Award and Officer of the British Empire (OBE).

Cohen, Samuel M., MD, PhD

Dr. Samuel M. Cohen (MD, PhD, University of Wisconsin – Madison, 1972) completed a residency in anatomic and clinical pathology at St. Vincent Hospital, Worcester, Massachusetts, in 1975, and became board certified in pathology the following year. He was a visiting professor in the department of Dr. Nobuyuki Ito at Nagoya City University Medical School, Nagoya, Japan, (1976 to 1977) a staff pathologist at St. Vincent Hospital (1975 to 1981), and associate professor of pathology at the University of Massachusetts Medical School (1977 to 1981). In 1981, he became Professor and Vice Chairman of Pathology in the College of Medicine and Professor at the Eppley Institute, University of Nebraska Medical Center. In 1992, he was named Chairman of the Department of Pathology and Microbiology at Nebraska, continuing in that position until 2007. Dr. Cohen’s research has focused on mechanisms of carcinogenesis, with a focus on the role of cell proliferation in the carcinogenic process, primarily utilizing the urinary bladder as a model system. Most recently this has involved investigations into the mechanisms of bladder carcinogenesis produced by arsenicals and PPAR agonists. Research with PPAR agonists has led to investigations into mechanisms of induction of hemangiosarcomas. In addition, his research has involved clinical investigations of various aspects of urologic pathology and extrapolation between animals and humans. This research has resulted in more than 350 publications. He has been a member of numerous NIH, EPA, FDA, IARC and National Academy of Sciences study sections and scientific panels, and was a member of the National Toxicology Program’s Board of Scientific Counselors and Board of Scientific Counselors of the National Institute of Environmental Health Sciences (NIEHS). He is a member of the FEMA Expert Panel (Chairman, 2014-2016). He is on the editorial boards of several scientific journals in the areas of toxicology, pathology, and carcinogenesis, and is a reviewer for several other journals. He was president of the SOT Carcinogenesis Specialty Section and the SOT Central States Chapter of the Society of Toxicology, and recipient of the Society’s Arnold J. Lehman Award in 2001. He was named Distinguished Scientist in Cancer Research by the Japanese Foundation for Cancer Research in 2004, and received the George H. Scott Award from the Toxicology Forum and the Lifetime Achievement Award from the Association for Environmental Health and Science in 2012. He continues to be active in human surgical pathology. He has been actively involved with ILSI, RSI, and HESI since 1985, serving as a member of the HESI Board of Trustees since 2001 (Vice Chairman, 2004-6; Chairman, 2006-8) and the ILSI Board since 2007 (Vice Chairman, 2010-2012, Chairman, 2012-2015).

Fukushima, Shoji, MD, PhD

Dr. Shoji Fukushima graduated from medical school in 1967, received his MD in 1968, and his PhD in 1973 under the supervision of Prof. Hisamasa Sato, all from Nagoya City University Medical School, Japan. He became a faculty member at Nagoya City University in 1968, and was associate research fellow in the Department of Pathology, University of Massachusetts Medical School, 1977-79. In 1979, Dr. Fukushima returned to the First Department of Pathology, Nagoya City University Medical School as assistant professor (Chairman, Prof. Nobuyuki Ito), and in 1980 was promoted to associate professor. In 1990, he became Professor and Chairman of the First Department of Pathology, Osaka City University Medical School, Japan, also serving as Dean in 2002-06. In 2006, he retired from Osaka City University and became Director of the Japan Bioassay Research Center, Japan Industrial Safety and Health Association. He
made significant contributions as a member of numerous scientific organizations and as a member of several editorial boards, including Cancer Letters, Pathology International, Cancer Science, Japanese Journal of Clinical Oncology and Asian Pacific Journal of Cancer Prevention. He served on numerous Japanese governmental committees, including the Food Additive Expert Commission (Former Chairman), the Food Safety Committee of the Cabinet Office, Chairman of the Commission for grants of food safety research from the Ministry of Health, Labor and Welfare, and a member of the Chemical Council of the Ministry of Economy, Trade and Industry. He has been a member of numerous national and international panels and committees, including serving on several IARC panels. His research interests are: 1) chemical carcinogenesis, particularly of the urinary bladder; 2) cancer risk assessment; 3) low dose extrapolation and thresholds in carcinogenesis; and 4) the pathology of urinary bladder. Especially he has focused on nanomaterial toxicity for his recent research.

**Hanson, Laurie A., DVM, PhD, DABT**  
Dr. Hanson is currently an Executive Director at Pfizer where she heads up the Study Management Group within Drug Safety Research & Development. She's responsible for the GLP general toxicology study conduct and pathology groups in Groton, CT as well as Global Resource Management and Global Strategic Outsourcing for all of DSRD. She has held a number of scientific and management roles working in a wide variety of drug safety areas and supporting a number of therapeutic areas. She received a DVM in 1988 from Kansas State University and a PhD in Pharmacology from University of Kansas Medical Center in Kansas City in 1992. In 1995 she became a Diplomate of the American Board of Toxicology. Laurie has been actively involved with HESI since 2000 when she served as the first Chair of the ILSI/HESI Nonclinical Cardiovascular Safety Studies Subcommittee on QT interval prolongation and presented work on behalf of HESI at numerous meetings. In addition to being President of the HESI Board of Trustees, Laurie is currently a member of the Executive Committee, the Finance Committee and the Membership Development Committee.

**Lee, Jerry S.H., PhD**  
Dr. Lee serves as a Health Sciences Director within the National Cancer Institute’s (NCI) Office of the Director where his chief responsibility is to help direct the NCI’s Center for Strategic Scientific Initiatives (CSSI). In this role, he provides leadership and input in planning, developing, and implementing rapid strategic scientific and technology initiatives that keep the Institute ahead of the scientific curve with respect to potential new exciting areas and discoveries. This may involve direct development and application of advanced technologies, creation of new trans-disciplinary teams, and/or use of available federal funding mechanisms to forge novel partnerships that emphasize innovation and convergence of scientific disciplines. Specifically, Dr. Lee oversees scientific, programmatic, and operational aspects of CSSI’s portfolio (~$161.3 million in FY14) and provides leadership in planning, developing, and implementing various CSSI programs. Since its inception in 2003, the Center has supported ~1,700 trans-disciplinary projects (~$1,088 million FY05 – FY14) through programs such as Innovation Molecular Analysis Technologies (IMAT), NCI Alliance for Nanotechnology in Cancer, The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), Physical Sciences-Oncology Centers (PS-OC), Provocative Questions (PQ), and Cancer Target Discovery and Development (CTD) network. These exploratory initiatives focus on the integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation of publicly available, broadly accessible, multi-dimensional data, knowledge, and tools to empower the entire cancer research continuum for patient benefit. Prior to joining the NCI, Dr. Lee’s research experience involved elucidating mechanisms of age-related diseases by combining cell biology, molecular biology, and engineering approaches to understand various cellular reactions to external stimuli. He has co-authored over twenty papers, five book chapters, and one book on the role of Rho GTPase-mediated nuclear and cellular mechanical responses to fluid flow and 3D culture and demonstrated their potential impact in diseases such as progeria and cancer. Dr. Lee continues research through his adjunct assistant professor at Johns Hopkins University, where he also earned his bachelor's degree in biomedical engineering and Ph.D. in chemical and biomolecular engineering. Dr. Lee also holds an appointment at the Washington D.C. Veterans Affairs Medical Center and collaborates with clinicians on next generation patient-centered outcomes research. He is an active member of the American Association for Cancer Research, Biomedical Engineering Society,
Biophysical Society, American Society of Mechanical Engineers, American Society for Cell Biology, and Tau Beta Pi. Dr. Lee also serves as member of the Innovation Policy Forum of the National Academies Board on Science, Technology, and Economic Policy, Foundation for the NIH’s Biomarkers’ Consortium Cancer Steering Committee, Health and Environmental Sciences Institute Board of Trustees, and the editorial board of Convergence Science Physical Oncology journal.

**Lehman-McKeeman, Lois, PhD**

Dr. Lois Lehman-McKeeman is Distinguished Research Fellow, Discovery Toxicology, at Bristol-Myers Squibb (BMS) in Princeton, NJ, where she has worked since 2001. Prior to joining BMS, she was employed in the Human and Environmental Safety Division of the Procter and Gamble. Dr. Lehman-McKeeman leads Discovery Toxicology and has active research interests broadly in biochemical mechanisms of toxicity. Her research also includes emphasis on the application and integration of metabolomic and transcriptomic technologies in mechanistic toxicology. She has published extensively in these fields. Dr Lehman-McKeeman received a BS degree in Toxicology from the University of the Sciences in Philadelphia and holds a Ph.D. in Toxicology from the University of Kansas Medical Center. She has been active professionally in the Society of Toxicology (SOT) serving on numerous SOT committees, and she has held elective office in the SOT as Councillor from 2000-2002 and the SOT Awards Committee (2008-2010). She was elected as Vice-President elect of the SOT in 2011, serving as President of the SOT in 2013-2014. In 2003, she was appointed Editor of *Toxicological Sciences*, a position she held through completion of the 2011 journal year. She has also served on a number of other editorial boards. Dr. Lehman-McKeeman has served on numerous national and international advisory committees for USEPA, NIH and IARC and the International Life Sciences Institute (ILSI). She was elected as a Fellow of the American Association for the Advancement of Science (AAAS) in 2008, and she is a fellow in the Academy of Toxicological Sciences. She was also the recipient of the Robert Scala Award in Toxicology for research excellence in an industrial laboratory (1994), the Society of Toxicology Achievement Award (2003) and the George H. Scott Award for scientific excellence from the Toxicology Forum (2006).

**Smith, Lewis L., PhD, FRCPath, FBTS**

Professor Lewis Smith is retired from all salaried positions. He remains a Professor at the University of Leicester and contributes informally to research and risk assessment activities. Professor Smith began his career in 1971 at ICI Central Toxicology Laboratories and during which time completed his PhD studies under the supervision of Professor Norman Aldridge at the MRC Toxicology Unit in Carshalton. He left ICI in 1991 to become Director of the MRC Toxicology Unit which he relocated two years later from Carshalton to its current location within the University of Leicester. Professor Smith has published extensively on the mechanisms of toxicity of chemicals, pesticides and drugs and is particularly interested in the extrapolation of experimental data to man. In 1998 he moved as Director to Zeneca Central Toxicology Laboratory and assumed responsibility for Health and Environmental Safety. In 2002 he transferred to Syngenta Basel as Head of Development and then to other appointments in Research and Development. On retiring from Syngenta he returned to the University of Leicester. Professor Smith is a past President of the British Toxicology Society as well as having held various positions on the Society’s committees. He is a past President of HESI and is currently a Trustee (Board member) of both HESI and ILSI. Professor Smith is also an ex-Board member of IUTOX. He is currently a member an executive of the North West Cancer Research Centre. This is a new centre committed to reducing the incidence and mortality from cancer. The majority of the research will be carried out at Liverpool University, although other academic and medical institutions from the North West Region of England will contribute.
van Ravenzwaay, Bennard, Dr. rer. nat. Dr. Bennard van Ravenzwaay is senior vice president, experimental toxicology and ecology at BASF SE in Ludwigshafen, Germany. The experimental toxicology and ecology section is responsible for the conduct of all toxicological and ecotoxicological studies necessary for the notification and registration of chemicals, agrochemicals and cosmetic ingredients. Dr. van Ravenzwaay is a member of the following scientific organizations and societies: chairman of the scientific committee of the European Centre for Ecotoxicology and Toxicology, member of the toxicology expert group of the European Crop Protection Association, the Program Committee for the German Society for Pharmacology and Toxicology, the German Society for Pharmacology and Toxicology, Eurotox, and the Society of Toxicology. He is a member of the editorial boards of both “Archives of Toxicology” and “Frontiers in Research.” He has authored or co-authored over 150 publications. He is a professor for toxicology at the University of Wageningen, Netherlands.
Autrup, Herman Nybro, PhD

Prof. Herman Autrup is past-President, EUROTOX, president, IUOTOX, and holds positions as Professor of Environmental Medicine at the University of Aarhus in Århus, Denmark, Adjunct Professor at the Chulabhorn Graduate Institute in Bangkok, Thailand, and Extra-ordinary Professor, School of Public Health, University of Pretoria, South Africa. He received his PhD in Experimental Pathology from the University of Nairobi in 1995 and a Candidatus Scientiarum in Organic Chemistry from the University of Copenhagen in 1971. He is member of the Danish Academy of Technical Sciences and a fellow of ATS (board member). His research interest is molecular epidemiology, with focus on molecular markers of susceptibility and exposure, air pollution. He is currently coordinating an interdisciplinary project on the safety of nanoparticles. Prof. Autrup is a member of several editorial boards including Tox Sci, and is invited reviewer for 15 different journals in the area of environmental toxicology and nanotoxicology, and is often invited to give lectures at international meetings and international research institutes. He has authored more than 200 publications in peer-reviewed journals and more than 50 publications in books and meeting proceedings and is the co-editor of 6 books. He received the European Environmental Mutagen Society' Fritz Sobel award in 2006 for his contribution in the area of carcinogen-DNA adducts, the Princess Chulabhorn of Thailand’s Gold Medal Award in 2007, EUROTOX Merit award in 2013 and the SOT Educational award in 2014. He is a member of the Society of Toxicology (USA), and the European Society of Toxicology (honorary member).

Beken, Sonja, PhD

Dr. Sonja Beken obtained her Master in Biological Sciences at the Vrije Universiteit Brussel (VUB), Belgium, holds a PhD in Pharmaceutical Sciences (VUB) and a Master in Applied Toxicology from the University of Surrey, UK. Sonja Beken is the Head of the Unit of non-clinical evaluators within the Belgian Federal Agency for Medicines and Health Products (FAMHP). This Unit is responsible for the evaluation of non-clinical data (pharmacology, pharmacokinetics and toxicology) submitted to support all phases of the life cycle of drug development (e.g. marketing authorization applications, clinical trial applications, EU and national scientific advice, paediatric investigation plans, etc). She is Vice-Chair of the Safety Working Party (SWP), Chair of the CVMP/CHMP Joint Ad Hoc Expert Group on 3R’s (JEG 3Rs), both at the European Medicines Agency (EMA) and she is Group Leader of the Informal S5(R3) Working Group at the level of the International Conference on Harmonisation (ICH). In June 2014 she was elected as Member of the Board Of Trustees of HESI (Health and Environmental Sciences Institute, US). Her main areas of expertise relate to regulatory science, non-clinical drug development, (in vitro) toxicology and metabolism as well as alternative models to animal experiments (3Rs).

Belanger, Scott E., PhD

Dr. Scott Belanger is presently a Research Fellow in Procter & Gamble’s corporate Global Product Stewardship safety organization where he has broad leadership responsibilities for environmental toxicology, science, and technology guidance from an environmental perspective. He holds degrees from the University of Wisconsin (B.S.), Bowling Green State University (M.S.) and Virginia Tech (PhD and post-doctoral appointment). Prior to joining P&G in 1989, he was an Assistant Professor in Environmental Toxicology at the University of Louisiana-Lafayette. During his tenure at P&G Scott directed research at P&G’s Experimental Stream Facility in southwestern Ohio evaluating the ecological impacts of P&G’s highest volume detergent chemicals. Later he assumed responsibility for P&G’s global environmental toxicology function including guidance for upstream technology development on environmental matters. Scott is a recognized authority in the responses of aquatic life to man-made and natural stressors and has authored over 100 published scientific articles, books and book chapters on these topics. He has served on numerous national and international panels providing advice to organizations such as the U.S. Environmental Protection Agency, the OECD (Organization for Economic Co-operation and Development, an international governing body), the European Commission, the Japanese Ministry of Environment, Trade and Industry, and Environment Canada. Presently in P&G’s Corporate Global Product Stewardship, Environmental Stewardship & Sustainability organization, he directs research on ecological and toxicological
responses of fish, invertebrates and algae to consumer product chemicals and advises P&G broadly on the development of new technologies and issues relating to sustainable development.

**Berridge, Brian R., DVM, PhD, DACVP**

Dr. Brian Berridge is Director and Head of WW Animal Research Strategy in the Office of Animal Welfare, Ethics and Strategy at GlaxoSmithKline. In that position he leads efforts to advance the scientific impact of animal and non-animal modeling in support of pharmaceutical development. He has held previous positions as a Director of Regulatory & Discovery Pathology at GSK and Principal Research Pathologist at Eli Lilly & Company. Brian is an Oklahoma State University-trained veterinarian with residency and PhD training from Texas A&M University. He is a Diplomate of the American College of Veterinary Pathologists and holds an adjunct Associate Professor position in the Department of Population Health and Pathobiology at North Carolina State University. He additionally teaches cardiovascular toxicology at the University of North Carolina. He is a member of the Executive Board and Board of Trustees for the ILSI Health and Environmental Sciences Institute where he also co-chairs the HESI Cardiac Safety Technical Committee, the Integrated CV Strategies Working Group, and the Translational Preclinical Imaging Technical Committee. Brian also chairs an international effort to harmonize cardiovascular nomenclature in regulatory toxicologic pathology and a CV Specialty Interest Group within the Society of Toxicologic Pathologists.

**Boobis, Alan R., OBE, PhD**

Dr. Alan Boobis is currently Professor of Biochemical Pharmacology and Director of the Public Health England Toxicology Unit at Imperial College London. He has been a member of Imperial College London for almost 40 years. His main research interests lie in mechanistic toxicology, drug metabolism, mode of action and chemical risk assessment. He has published around 230 original research papers (H-factor 63). He is a member of several national and international advisory committees, the Committee on Toxicity (chair), the WHO Study Group on Tobacco Product Regulation (TobReg), JECFA (veterinary residues – co-chair) and JMPR (alternating co-chair). He has been a member of the UK Advisory Committee on Pesticides, Committee on Carcinogenicity, the EFSA CONTAM Panel and the EFSA PPR Panel. He is a member and a past chairman of the Board of Trustees of ILSI (International Life Sciences Institute) HESI, vice-president of ILSI Europe and chair of ILSI. He is involved in several HESI, ILSI RF and ILSI Europe projects. Awards include fellowship of the Society of Biology and the British Toxicology Society, the BTS John Barnes Prize Lectureship, honorary membership and Merit Award of EUROTOX, the Royal Society of Chemistry Toxicology Award and Officer of the British Empire (OBE). He is the recipient of an Honorary Doctorate from Maastricht University.

**Brewster, David, PhD, DABT**

Dr. David Brewster is a Board certified toxicologist with >30 years of research experience in toxicology and nearly 20 years experience in the pharmaceutical industry. He has extensive experience in the development of new molecular entities (both small and large molecules), medical devices, reformulations of marketed products and global product registration and support. At Monsanto he developed and led the thyroid biochemical toxicology and cell proliferation programs. During his tenure at Aventis and its predecessor companies he built and staffed an investigative toxicology group and assumed increasing responsibilities up to the Director of Toxicology and Head of US projects. At Purdue he reorganized and re-energized the organization and integrated the toxicology, pathology, bioanalytical, drug metabolism and toxicokinetic groups into a high performing team. At Roche he was Vice-President NonClinical Drug Safety responsible for preclinical safety assessment and NCS Site Head in Nutley, NJ with oversight of the toxicology, pathology, drug metabolism, bioanalytics, and pharmacokinetics/toxicokinetics groups and responsible for setting policy and directing strategic planning for non-clinical safety testing. Currently at Vertex as VP and Head Global Drug Safety Evaluation he is responsible for Global strategic preclinical regulatory strategies, providing scientific advice and oversight for early and late stage drug development projects. In addition his responsibilities include establishment of Scientific and Educational programs, building the presence and recognition of Vertex to academia, US trade organizations, and professional drug development organizations and represents the company externally on various Scientific and Pharma trade organizations. His interests not only include drug development and working collaboratively with the FDA but also seeking alternatives to classical toxicology testing, evaluating the application of stem cell technologies and investigating the use non-invasive biosensors and whole body imaging in safety assessment.
Cohen, Samuel M., MD, PhD

Dr. Samuel M. Cohen (MD, PhD, University of Wisconsin – Madison, 1972) completed a residency in anatomic and clinical pathology at St. Vincent Hospital, Worcester, Massachusetts, in 1975, and became board certified in pathology the following year. He was a visiting professor in the department of Dr. Nobuyuki Ito at Nagoya City University Medical School, Nagoya, Japan, (1976 to 1977) a staff pathologist at St. Vincent Hospital (1975 to 1981), and associate professor of pathology at the University of Massachusetts Medical School (1977 to 1981). In 1981, he became Professor and Vice Chairman of Pathology in the College of Medicine and Professor at the Eppley Institute, University of Nebraska Medical Center. In 1992, he was named Chairman of the Department of Pathology and Microbiology at Nebraska, continuing in that position until 2007. Dr. Cohen’s research has focused on mechanisms of carcinogenesis, with a focus on the role of cell proliferation in the carcinogenic process, primarily utilizing the urinary bladder as a model system. Most recently this has involved investigations into the mechanisms of bladder carcinogenesis produced by arsenicals and PPAR agonists. Research with PPAR agonists has led to investigations into mechanisms of induction of hemangiosarcomas. In addition, his research has involved clinical investigations of various aspects of urologic pathology and extrapolation between animals and humans. This research has resulted in more than 350 publications. He has been a member of numerous NIH, EPA, FDA, IARC and National Academy of Sciences study sections and scientific panels, and was a member of the National Toxicology Program’s Board of Scientific Counselors and Board of Scientific Counselors of the National Institute of Environmental Health Sciences (NIEHS). He is a member of the FEMA Expert Panel (Chairman, 2014-2016). He is on the editorial boards of several scientific journals in the areas of toxicology, pathology, and carcinogenesis, and is a reviewer for several other journals. He was president of the SOT Carcinogenesis Specialty Section and the SOT Central States Chapter of the Society of Toxicology, and recipient of the Society’s Arnold J. Lehman Award in 2001. He was named Distinguished Scientist in Cancer Research by the Japanese Foundation for Cancer Research in 2004, and received the George H. Scott Award from the Toxicology Forum and the Lifetime Achievement Award from the Association for Environmental Health and Science in 2012. He continues to be active in human surgical pathology. He has been actively involved with ILSI, RSI, and HESI since 1985, serving as a member of the HESI Board of Trustees since 2001 (Vice Chairman, 2004-6; Chairman, 2006-8) and the ILSI Board since 2007 (Vice Chairman, 2010-2012, Chairman, 2012-2015).

Davis, Myrtle A., DVM, PhD

Dr. Myrtle Davis is the currently the Branch Chief for Toxicology and Pharmacology in the Developmental Therapeutics Program of the Division of Cancer Diagnostics and Treatment of the National Cancer Institute and serves as Scientific Director of the Laboratory of Investigative Toxicology at the Frederick National Laboratory for Cancer Research (FNLCR). Dr. Davis contributes broadly to the DCTD by providing mechanistic toxicology expertise to drug discovery and development teams, creating and leading major research initiatives within DTP and managing the daily operations of the Toxicology and Pharmacology Branch. The branch is responsible for developing safety evaluation strategies to establish toxicity profiles for new investigational agents in the NCI's Investigational Therapeutics Experiments NExT (NExT). The branch also provides expertise in discussions with the FDA about the design and adequacy of planned (or completed) nonclinical toxicology studies that are expected to support Investigational New Drug Applications. Prior to her appointment at NCI in 2008, Dr. Davis was a Research Advisor in the Investigative Toxicology Group at Lilly Research Labs, Eli Lilly and company. Prior to taking the position at Eli Lilly in 2002, Dr. Davis was an Associate Professor in the Department of Pathology at the University of Maryland, School of Medicine where she had an active grant-supported research program exploring mechanisms of toxicant-induced apoptosis and the role of protein phosphorylation. Dr. Davis is an active member of the Society of Toxicology and is a long-standing member of the Society of Toxicological Pathology. She currently serves on SOT Council and on the Board of Trustees for the ILSI Health and Environmental Sciences Institute as an outside activity. She was a member of the Institute for Laboratory Animal Research Council; The National Academies of Sciences for a six-year term ending in 2012. She served as Co-Editor in Chief for the ILAR Journal and has served and an Associate Editor for various Toxicology sand Journals including Toxicological Sciences. She also served as a member of the standing NIH Study Section, ALTX1 for 5 years. She has authored several book chapters and co-authored peer-reviewed publications on a range of topics including apoptosis, toxicant-induced cell signaling and biomarkers of tissue injury. She has also developed course content and lectures for medical and graduate student education. A native New Yorker, Dr. Davis completed a postdoctoral fellowship in
Toxicologic Pathology at the University of Maryland. She earned a PhD in Toxicology from the University of Illinois Champaign-Urbana and obtained her Doctor of Veterinary Medicine degree from Tuskegee University School of Veterinary Medicine. She also completed undergraduate work in Chemistry and Math at Tuskegee University.

Devlin, Dennis J., PhD

Dr. Dennis Devlin joined Exxon Biomedical Sciences in 1987. His early work focused on site remediations and product risk assessments. He transferred to the Brussels headquarters of Exxon Chemical International, Inc. in 1991 where he directed the toxicology program for European Exxon business groups and area offices. Following the merger of Exxon and Mobil, he became Director of Toxicology and Environmental Sciences, providing global affiliates and support organizations with consulting services, science development, and field support. In 2009, he assumed the role of Sr. Environmental Health Advisor for Exxon Mobil Corporation where he provides strategic guidance for environmental health policy and planning. Dennis is a Board Trustee of the International Life Sciences Institute (ILSI) and past president of the ILSI Health and Environmental Sciences Institute, Chairman of the Petroleum Industry High Production Volume Testing Committee, Chairman of the American Petroleum Institute's Exploration and Production Health Issues Group, and a member of the Institute of Medicine of the National Academies Roundtable on Environmental Health Sciences, Research, and Medicine. Dennis received a PhD in Toxicology from Dartmouth College.

Fukushima, Shoji, MD, PhD

Dr. Shoji Fukushima graduated from medical school in 1967, received his MD in 1968, and his PhD in 1973 under the supervision of Prof. Hisamasa Sato, all from Nagoya City University Medical School, Japan. He became a faculty member at Nagoya City University in 1968, and was associate research fellow in the Department of Pathology, University of Massachusetts Medical School, 1977-79. In 1979, Dr. Fukushima returned to the First Department of Pathology, Nagoya City University Medical School as assistant professor (Chairman, Prof. Nobuyuki Ito), and in 1980 was promoted to associate professor. In 1990, he became Professor and Chairman of the First Department of Pathology, Osaka City University Medical School, Japan, also serving as Dean in 2002-06. In 2006, he retired from Osaka City University and became Director of the Japan Bioassay Research Center, Japan Industrial Safety and Health Association. He made significant contributions as a member of numerous scientific organizations and as a member of several editorial boards, including Cancer Letters, Pathology International, Cancer Science, Japanese Journal of Clinical Oncology and Asian Pacific Journal of Cancer Prevention. He served on numerous Japanese governmental committees, including the Food Additive Expert Commission (Former Chairman), the Food Safety Committee of the Cabinet Office, Chairman of the Commission for grants of food safety research from the Ministry of Health, Labor and Welfare, and a member of the Chemical Council of the Ministry of Economy, Trade and Industry. He has been a member of numerous national and international panels and committees, including serving on several IARC panels. His research interests are: 1) chemical carcinogenesis, particularly of the urinary bladder; 2) cancer risk assessment; 3) low dose extrapolation and thresholds in carcinogenesis; and 4) the pathology of urinary bladder. Especially he has focused on nanomaterial toxicity for his recent research.

Guiney, Patrick D., PhD

Dr. Patrick Guiney is an Adjunct Professor of Environmental Toxicology at the University of Wisconsin-Madison. He was previously Director of Global Environmental Safety at S.C. Johnson & Son, Inc. where he was responsible for conceiving and implementing global environmental toxicology research strategies and policies. Dr. Guiney has 38 years of broad-based experience in human health and ecological risk assessments. He has served internationally as Chair of several multidisciplinary scientific committees and advisory panels including the EPA’s Endocrine Disrupter Screening and Testing Standardization and Validation Ecotoxicology Advisory Panel. He is currently serving as the Vice-President of the Society of Environmental Toxicology and Chemistry (SETAC)’s World Council (SWC). He has served on the SNA Board of Directors for 8 years, on the SETAC World Council for 7 years, and is a Charter Member of SETAC. Dr. Guiney is a co-developer of S.C. Johnson’s award-winning Greenlist™ Program (an integrated computer-based approach for designing superior performing, environmentally responsible products from concept to market). He is also co-recipient of EPA’s 2006 Green Chemistry Award for work on Greenlist™ and co-recipient of the 2006 Presidential Award for Corporate Leadership-Environmental Sustainability (The Ron Brown Award). Dr. Guiney received his PhD in Environmental Toxicology from the University of Wisconsin-Milwaukee. He has conducted research into the transport, bioaccumulation and fate of toxic substances at various levels of
biological organization (molecular/biochemical to field studies). His current research interests include the application of molecular based models for screening and prioritizing potential endocrine disruptors, quantitative structure-activity relationships for investigating mechanisms of toxicity, ecological exposure assessment modeling for risk assessment, and alternative methods for predicting the bioaccumulation of persistent chemicals. He also holds an adjunct faculty appointment at the University of Wisconsin-Milwaukee, and has published 46 peer-reviewed scientific papers in these areas of research.

Guzzie-Peck, Peggy J., PhD

Dr. Peggy J Guzzie-Peck holds M.S. and PhD degrees from the University of Pittsburgh in Toxicology/Human Genetics with an emphasis on Genetic Toxicology. She has broad experience in various aspects of toxicology and has been a diplomate of the American Board of Toxicology since 1987. Peggy joined Johnson & Johnson (Janssen Pharmaceuticals) in the Global Preclinical Development organization in 2007 and is currently the Global Head of Investigative Safety Sciences in the Discovery Sciences Department with responsibilities for managing investigative de-risking activities, a key member of the Scientific Advisory Board, developing innovative technologies strategies, managing postdoctoral and consortia relationships, and interfacing with the Janssen Innovation Centers. Previous role in Janssen as the Global Head of Toxicology/Pathology and Laboratory Animal Medicine, with responsibilities for developing the strategy and delivering the operational goals at sites both in Raritan, NJ and Beerse, Belgium. Before joining Johnson & Johnson PCD, she has held several management-level positions at Pfizer, Inc. where she headed Genetic Toxicology in Groton, CT for over 10 years and led other disciplines including Safety Pharmacology, General Toxicology and Comparative Medicine as an Executive Director of Toxicology in Amboise, France. Prior to her career at Pfizer, she managed the Genetic Toxicology group at G.D. Searle and coordinated the outsourcing of worker safety and environmental impact testing. Throughout her career, she has served on several international expert work groups in Preclinical Safety, Genetic Toxicology, In Vitro Toxicology, Photosafety and Safety Pharmacology. She was a member of the PhRMA Preclinical Safety Leadership committee, chaired the PhRMA Genetic Toxicology and Phototoxicity Technical Groups, served on the council for the Environmental Mutagen Society, and chaired the Genetic Toxicology Association. She has also taught courses and lectured at several universities on various topics including Preclinical Safety Testing, Structural Activity Relationships, Carcinogenicity, Toxicoinformatics, and Genetic Toxicology.

Hanson, Laurie A., DVM, PhD, DABT

Dr. Laurie Hanson is currently an Executive Director at Pfizer where she heads up the Study Management Group within Drug Safety Research & Development. She’s responsible for the GLP general toxicology study conduct and pathology groups in Groton, CT as well as Global Resource Management and Global Strategic Outsourcing for all of DSRD. She has held a number of scientific and management roles working in a wide variety of drug safety areas and supporting a number of therapeutic areas. She received a DVM in 1988 from Kansas State University and a PhD in Pharmacology from University of Kansas Medical Center in Kansas City in 1992. In 1995 she became a Diplomate of the American Board of Toxicology. Laurie has been actively involved with HESI since 2000 when she served as the first Chair of the ILSI/HESI Nonclinical Cardiovascular Safety Studies Subcommittee on QT interval prolongation and presented work on behalf of HESI at numerous meetings. In addition to being President of the HESI Board of Trustees, Laurie is currently a member of the Executive Committee, the Finance Committee and the Membership Development Committee.

Harpur, Ernie, BSc, PhD

Following periods of doctoral and post-doctoral research in toxicology, Dr. Ernie Harpur spent 13 years in academia where his research interests centered on investigations of mechanisms of toxicity. Ernie subsequently worked for 21 years in Drug Safety Assessment in pharmaceutical industry based in Europe and the USA, for the last 9 years as Global Head of Scientific Affairs and Regulatory Standards. Since leaving industry in 2010, Ernie has held an honorary position in Toxicology within the Institute of Cellular Medicine at Newcastle University and engaged in various scientific advisory roles. He is active in several professional societies (past Scientific Secretary of the British Toxicology Society (BTS) and past President of EUROTOX). He is a Fellow of the BTS, a Fellow of the Academy of Toxicological Sciences and an honorary member of EUROTOX. He has served on several expert committees, including the Safety, Efficacy and Adverse Reactions Sub-Committee of the UK Committee on Safety of Medicines. He has contributed to a number of scientific consortia on both sides of the Atlantic e.g. as a leader of the HESI Renal Biomarkers Committee, as Vice Chair of the HESI...
Emerging Issues Committee, as a member of the Advisory Committee of the Predictive Safety Testing Consortium of the Critical Path Institute and as chair of the Scientific Advisory Board of the UK public private partnership, Stem Cells for Safer Medicines. Currently he is Vice Chair of the HESI Board of Trustees, Executive Committee and Program Strategy and Stewardship Committee. He is Vice President of the BTS and a member of the editorial boards of Toxicology Letters and Human & Experimental Toxicology.

Lau, Serrine S., PhD

Dr. Serrine Lau received her PhD in Pharmacology from the University of Michigan. She was a Postdoctoral Fellow and Senior Staff Fellow with Dr. James Gillette and Dr. Michael Boyd at NHLBI and NCI, NIH, respectively. Dr. Lau is a Professor of Pharmacology and Toxicology, Director of the Southwest Environmental Health Sciences Center and Director of the Arizona Board of Reagents Center for Toxicology in the College of Pharmacy at the University of Arizona. Prior to her current position, Dr. Lau spent 17 years in the Division of Pharmacology and Toxicology at the University of Texas at Austin, and served as the Director of the NIEHS-supported Toxicology Training Program. Dr. Lau's research focuses on three areas: (i) mechanisms of chemical-induced nephrotoxicity and nephrocarcinogenicity (ii) prostanoid and retinoid-mediated cytoprotection against ROS induced tissue injury, and (iii) proteomics approaches for the identification of chemical-induced protein post-translational modifications, and biomarker discovery for diseases including diabetes, asthma and cancer. Dr. Lau collaborates extensively with basic and clinical scientists, integrating the basic sciences with translational opportunities in environmental health sciences research. Dr. Lau has over 150 publications and 300 published abstracts. Dr. Lau’s research work has been funded by grants from the National Institutes of Health, National Science Foundation, the American Association of Colleges of Pharmacy, and the Pharmaceutical Manufacturers Association Foundation. Dr. Lau plays an active role in a number of professional organizations serving the field of toxicology and the environmental health sciences. She has served on many elected and appointed committees at SOT, ASPET, ISSX, NIH Study Section grant review panels and National Academy of Sciences. She completed her appointment as a member of the HESI Emerging Issues Steering Committee (June 2011), Chair of SOT Awards Committee (May 2012) and Chair of the SOT Board of Publications (May 2013). She is currently a member of the HESI Board of Trustees, HESI Treasurer and a member of the NIEHS Board of Scientific Counselors.

Lehman-McKeeman, Lois, PhD

Dr. Lois Lehman-McKeeman is Distinguished Research Fellow, Discovery Toxicology, at Bristol-Myers Squibb (BMS) in Princeton, NJ, where she has worked since 2001. Prior to joining BMS, she was employed in the Human and Environmental Safety Division of the Procter and Gamble. Dr. Lehman-McKeeman leads Discovery Toxicology and has active research interests broadly in biochemical mechanisms of toxicity. Her research also includes emphasis on the application and integration of metabolomic and transcriptomic technologies in mechanistic toxicology. She has published extensively in these fields. Dr. Lehman-McKeeman received a BS degree in Toxicology from the University of the Sciences in Philadelphia and holds a PhD in Toxicology from the University of Kansas Medical Center. She has been active professionally in the Society of Toxicology (SOT) serving on numerous SOT committees, and she has held elective office in the SOT as Councillor from 2000-2002 and the SOT Awards Committee (2008-2010). She was elected as Vice-President elect of the SOT in 2011, serving as President of the SOT in 2013-2014. In 2003, she was appointed Editor of Toxicological Sciences, a position she held through completion of the 2011 journal year. She has also served on a number of other editorial boards. Dr. Lehman-McKeeman has served on numerous national and international advisory committees for USEPA, NIH and IARC and the International Life Sciences Institute (ILSI). She was elected as a Fellow of the American Association for the Advancement of Science (AAAS) in 2008, and she is a fellow in the Academy of Toxicological Sciences. She was also the recipient of the Robert Scala Award in Toxicology for research excellence in an industrial laboratory (1994), the Society of Toxicology Achievement Award (2003) and the George H. Scott Award for scientific excellence from the Toxicology Forum (2006).

McQueen, Charlene A., PhD, ATS

Dr. Charlene McQueen assumed the position of Director of the Integrated Systems Toxicology Division in the US EPA National Health and Environmental Effects Research Laboratory in January 2011. Prior to that, she held positions at the Harrison School of Pharmacy, Auburn University (2007-2011) and the Department of Pharmacology and Toxicology at the University of Arizona (1990-2007). Dr. McQueen received a B.S. in Biology from Marywood College, Scranton, PA, M.S. in
Philbert, Martin A., PhD

Dr. Martin Philbert became dean of the University of Michigan School of Public Health on January 1, 2011, having previously served as senior associate dean for research at the school since 2004. He arrived at UM in 1995 from Rutgers' Neurotoxicology Laboratories, where he was a research assistant professor. He has maintained a continuously federally funded portfolio of basic research activities throughout his career. Most recently his work has been funded by the National Institutes of Health, the Department of Air Force and the National Cancer Institute. At the national level, he is recognized for his expertise in neurotoxicology and experimental neuropathology. Dr. Philbert earned his PhD in Neurochemistry/Experimental Neuropathology in 1987 from London University (England). He is the author of numerous research publications in top peer-reviewed journals, and one book. In 2012, Dr. Philbert was elected to membership in the Institute of Medicine of the National Academy of Sciences, and has been a member of numerous international and national panels, committees, and advisory boards. He is a frequent lecturer on toxicology and risk assessment subjects. He has been a member of the SOT Council (1999-2001), the Council of the International Society for the Study of Xenobiotics (ISSX) (1994-1997) and the Executive Committee of the Drug Metabolism Division of the American Society of Pharmacology and Experimental Therapeutics (1997-2000). Dr. McQueen was on the Environmental Health Sciences Committee of the National Institute of Environmental Health Sciences, the Board of Scientific Councilors of the National Toxicology Program and the National Institutes of Health Cancer Etiology Study Section. Currently, Dr. McQueen is a member of the HESI Board of Trustees, the Board Secretary and a member of the ISSX Committee on Regulatory Affairs.

Moretto, Angelo, MD, PhD

Dr. Angelo Moretto is a professor of Occupational Medicine and Toxicology in the Department of Biomedical and Clinical Sciences at the University of Milan (Milan, Italy). Since 2006, he is also Director of the International Center for Pesticides and Health Risks Prevention (ICPS) at “Luigi Sacco” Hospital (Milan, Italy). He has been and currently is a member of many international and national committees for the risk assessment of exposure to chemical substances, in particular pesticides, and for the improvement, harmonization and innovation of risk assessment methods. Currently, he is a member of the following scientific organizations: Academy of Toxicological Sciences, International Commission on Occupational Health, International Neurotoxicology Association (Board member 2007-2009), Società Italiana di Medicina del Lavoro e Igiene Industriale (Board Member 2011-2014), Società Italiana di Tossicologia (Board Member since 2015), and the Society of Toxicology. Prof. Moretto sits on the Editorial Board of the journal Regulatory Toxicology and Pharmacology, acts as reviewer for over 15 journals, and has authored more than 80 papers in peer-review journal on toxicology, mainly neurotoxicology of pesticides, occupational toxicology, and toxicological risk assessment, and more than 20 review papers and book chapters.

Pastoor, Timothy P., PhD, DABT

Dr. Timothy Pastoor obtained his PhD in toxicology from the University of Michigan, is certified by the American Board of Toxicology (DABT), and is a long-standing, active member of the Society of Toxicology. Dr. Pastoor has over 30 years of international experience in fundamental toxicity testing, mode of action research, and human health risk assessment. For the majority of his career, including positions with DuPont, ICI, Zeneca, Novartis, and Syngenta, Dr. Pastoor led toxicology and risk assessment experts in the conduct of safety, health, and environmental studies to assess risk to humans and the environment. He retired in 2015 from Syngenta as Principal Scientist. In that role, he was involved in toxicological research projects and product development and was frequently asked to interact with media, community groups, legislators, and regulatory agencies. He is a frequent lecturer on toxicology and risk assessment subjects. Dr. Pastoor has been involved in numerous ILSI-HESI projects. He helped organize the first peroxisome proliferation workshop, was a co-author of the Human Relevancy Framework, and co-chair of the Agricultural Chemical Safety Assessment committee. He is currently co-chairing the RISK21 project and is HESI’s vice-president.
Platz, Stefan J., DVM, PhD, DABT

Dr. Stefan Platz joined AstraZeneca in February 2012 and is the Global Head Drug Safety and Metabolism (DSM) in AstraZeneca. In this function he is responsible for Toxicology, Pathology, DMPK and Laboratory Animal Sciences. Prior to joining AZ, Stefan was with Hoffmann-La Roche in Basel and before in Palo Alto, leading the non-clinical safety organizations at these sites and in addition had extended periods of responsibilities for the early safety as well as biologics safety strategy. He started his career in 1996 at Boehringer Ingelheim as a pathologist with short term secondments at the Ohio State University and as a fellow of the Pembroke College in Cambridge. In 2001 he contributed to the successful filing to Tenecteplase, a tissue plasminogen activator together with the preclinical expert at Genentech. Stefan received his veterinary degree from the University of Munich, is a German certified veterinary pathologist and a Diplomate of the American Board of Toxicology. He is particularly interested in exploring novel approaches and technologies to improve the understanding of human safety risks prior to testing in clinical trials.

Rowlands, J. Craig, PhD, DABT

Dr. Craig Rowlands is a Senior Scientist at The Dow Chemical Company's Toxicology and Environmental Research and Consulting Organization (TERC). He advises Dow businesses on their toxicology and risk assessment needs with a goal towards sustainable chemistry. He leads the TERC Science and Research activities, directing its Strategic Research Program that focuses on refinement and development of current and future toxicology testing and risk assessment capabilities. Dr. Rowlands is an adjunct professor at Michigan State University, Center for Integrative Toxicology and holds leadership positions in the Society for Toxicology, the American Chemistry Council and the International Life Sciences Institute, Health and Environmental Science Institute. He completed his PhD in Toxicology at Texas A&M University and performed postdoctoral research in molecular endocrinology at the Karolinska Institute in Stockholm, Sweden. Prior to coming to Dow, he worked at the US FDA. Dr. Rowlands is a Diplomate of the American Board of Toxicology (DABT) and a Fellow of the American College of Nutrition (FACN).

Sanbuissho, Atsushi, DVM, PhD

Dr. Atsushi Sanbuissho received his PhD degree from the Ohio State University in 1988. He was a post-doctoral fellow in the Department of Veterinary Physiology at the Ohio State University from 1988 to 1990. During this period, he studied mechanism of in vitro maturation and fertilization of bovine oocytes. Then, he was a researcher in the Department of Anatomy and Cellular Biology, Harvard Medical School from 1990 to 1992. He has focused on functional and ultra-structural characteristics of rat granulosa cells during developmental stage with the role of heterogeneity of cell type related to metabolic response associating transition from preantral to preovulatory stages of follicular differentiation. In 1992, he was an associate chief researcher of Medicinal Research Laboratories, SANKYO CO., LTD. He started research on teratogenicity potential of chemical compounds using rat and rabbit. Besides research work, he has been actively involved with consortium activities in ICH S5EWG. He was a chairman of Basic Research Committee in Japan Pharmaceutical Manufacturers Association (JPMA) from 2008-2009. He became a head of Medicinal Safety Research Laboratories, DAIICHI SANKYO CO., LTD. from 2009-2012. From 2011 to date, he has involved the project team of Human iPS/ES technology and it’s Application to toxicology testing.

Sato, Keiichiro, DVM, PhD, DJSOT, DABT

Dr. Keiichiro Sato is Director, Drug Safety Research Laboratories, at Takeda Pharmaceutical Company Limited in Kanagawa, Japan. He oversees all toxicology programs of marketed drugs and drug candidates for various therapeutic indications including cardiovascular and metabolic diseases. Dr. Sato has been with Takeda since 1988. He earned his DVM from the Ministry of Agriculture, Forestry and Fisheries (Tokyo) in 1988, and his PhD in Veterinary Medicine from the University of Tokyo in 1997. He is a Diplomate of the Japanese Society of Toxicology (JSOT) and the American Board of Toxicology. Dr. Sato has served in several JSOT leadership roles over the last decade, including his current role as a JSOT Councilor. Dr. Sato is the author of numerous publications and a frequent presenter at technical meetings throughout Japan, Europe, and the United States.
Smith, Lewis L., PhD, FRCPat, FBTS

Professor Lewis Smith is retired from all salaried positions. He remains a Professor at the University of Leicester and contributes informally to research and risk assessment activities. Professor Smith began his career in 1971 at ICI Central Toxicology Laboratories and during which time completed his PhD studies under the supervision of Professor Norman Aldridge at the MRC Toxicology Unit in Carshalton. He left ICI in 1991 to become Director of the MRC Toxicology Unit which he relocated two years later from Carshalton to its current location within the University of Leicester. Professor Smith has published extensively on the mechanisms of toxicity of chemicals, pesticides and drugs and is particularly interested in the extrapolation of experimental data to man. In 1998 he moved as Director to Zeneca Central Toxicology Laboratory and assumed responsibility for Health and Environmental Safety. In 2002 he transferred to Syngenta Basel as Head of Development and then to other appointments in Research and Development. On retiring from Syngenta he returned to the University of Leicester. Professor Smith is a past President of the British Toxicology Society as well as having held various positions on the Society’s committees. He is a past President of HESI and is currently a Trustee (Board member) of both HESI and ILSI. Professor Smith is also an ex-Board member of IUTOX. He is currently a member an executive of the North West Cancer Research Centre. This is a new centre committed to reducing the incidence and mortality from cancer. The majority of the research will be carried out at Liverpool University, although other academic and medical institutions from the North West Region of England will contribute.

Stevens, James L., PhD

Dr. James Stevens received his PhD in Pharmacology from the University of Minnesota in 1980 and was awarded a PRAT Fellowship from the National Institute of General Medical Sciences. He has held a number of positions including Senior Staff Fellow in the Bureau of Biologics, FDA (1983-1986), Senior Scientist (1986-1992) and then Executive Director (1992-1998) at the W. Alton Jones Cell Science Center, Lake Placid, NY, and Professor of Pathology at the University of Vermont (1998-2000). Dr. Stevens also served as a member of the Board of Directors for Upstate Biotechnology. He joined Lilly Research Laboratory in 2000 where he is a Distinguished Research Fellow. He was appointed a HESI Trustee in 2008 and to the NIGMS Science Advisory Council in 2009. He received the Achievement Award from the Society of Toxicology in 1994 and was elected a Fellow of the American Association for the Advancement of Sciences in 1996. His research interests focus on predictive and molecular/investigative toxicology and adverse drug reactions. He has published over 90 peer reviewed articles.

van den Berg, Martin, PhD

Dr. Martin van der Berg started his activities within the Research Institute Toxicology of the University of Utrecht as an Associate Professor in Environmental Toxicology. In 1999 he was appointed Professor Veterinary Environmental Sciences and Environmental Toxicology at the Research Institute Toxicology, Faculty of Veterinary Medicine of the Utrecht University. In 2007 his professorship was upgraded to a chair in Toxicology at the Faculty of Veterinary Medicine. Currently he holds the position of Deputy Director and Head, Toxicology and Veterinary Pharmacology Division of the Institute for Risk Assessment Sciences, University of Utrecht, NL. IRAS has 150-175 scientific and technical staff members annually and three divisions; Toxicology & Pharmacology, Environmental Epidemiology and Veterinary Public Health. His main roles and responsibilities include (1) the development of research programs in toxicology at IRAS with special emphasis for the effect of environmental and food contaminants. Special attention is given to the development of toxicokinetic modelling, development of in vitro models and metabolic or steroidogenic processes of both xenobiotics as well as natural hormone like compounds; (2) integration of the fields of environmental and biochemical toxicology with special emphasis on the use of biochemical and molecular techniques with special emphasis on the chemoprevention of hormone dependent tumors; (3) coordination and participation in national and international organizations and advisory boards for risk assessment; (4) presentation and publication of scientific results in international journals, conference symposia and workshops; (5) training and courses in Toxicology for under and postgraduate students at the University of Utrecht; and (6) thesis supervisor (promotor). In addition, he is appointed as an Honorary Professor in Environment Toxicology at the University of Queensland (Brisbane) and Adjunct Professor at the Royal Chulabhorn Research and Graduate Institute (Bangkok).

van der Laan, Jan Willem, PhD

Dr. Jan Willem van der Laan is senior assessor in Pharmacology and Toxicology for the Medicines Evaluation Board, located in Utrecht, the Netherlands. He is chair of the EMA/CHMP Safety Working Party. Dr. Van der Laan was since 1990 in the Section Pharmacology and Toxicology Assessment at the National Institute
for Public Health and the Environment (RIVM, Bilthoven). In this function he was responsible for the advice on non-clinical safety aspects for the Netherlands ‘College’, the Medicines Evaluation Board. He moved with this group in 2012 to the Medicines Evaluation Board located in Utrecht, and stepped back as leader of the group earlier. He is still senior assessor in this area. His contributions to the International Conference on Harmonization started in 1992 on Carcinogenicity Testing. Later he was EU rapporteur for S8 Immunotoxicity and for ICH S6 (R1) Addendum for the Preclinical testing of Biotechnology-derived Proteins. Now again, he is a member of the new Expert Working Group on Carcinogenicity testing, started in 2011. He is also member of the Informal Working Group on Reproductive Toxicity revising the S5. This group started in June 2014 in Minneapolis. In 2015 he became Regulatory Chair of the Expert Working Group on Juvenile Toxicity testing S11.

van Ravenzwaay, Bennard, PhD

Dr. Bennard van Ravenzwaay is senior vice president, experimental toxicology and ecology at BASF SE in Ludwigshafen, Germany. The experimental toxicology and ecology section is responsible for the conduct of all toxicological and ecotoxicological studies necessary for the notification and registration of chemicals, agrochemicals and cosmetic ingredients. Dr. van Ravenzwaay is a member of the following scientific organizations and societies: chairman of the scientific committee of the European Centre for Ecotoxicology and Toxicology, member of the toxicology expert group of the European Crop Protection Association, the Program Committee for the German Society for Pharmacology and Toxicology, the German Society for Pharmacology and Toxicology, Eurotox, and the Society of Toxicology. He is a member of the editorial boards of both “Archives of Toxicology” and “Frontiers in Research.” He has authored or co-authored over 150 publications. He is a professor for toxicology at the University of Wageningen, Netherlands.

Wallace, Kendall B., PhD

Dr. Kendall Wallace is a Professor and Associate Dean at the University of Minnesota Medical School on the Duluth campus. Dr. Wallace received his B.S. in Biochemistry from Michigan State University in 1975 and his PhD in Physiology in 1979 from the same institution. He completed a two-year postdoctoral fellowship in the Toxicology Center at the University of Iowa before accepting an academic appointment first in Pharmacology and then Biochemistry and Molecular Biology at the University of Minnesota, Duluth. He has received a number of academic awards and recognitions, including “Basic Science Teacher of the Year” on 4 occasions. Dr. Wallace’s research interest is on the mitochondrion as a target for chemical-induced toxicity and the biochemical and molecular mechanisms that mediate such metabolic diseases. Dr. Wallace is a Diplomate of the American Board of Toxicology and served as President of its Board of Directors in 2001-02. He is also Past-President of the Society of Toxicology and president of the Board of Directors of the Academy of Toxicological Sciences. He has served on the executive committees for the Toxicology Division of ASPET (1992-98) and the IUTOX International Congress of Toxicology (1993-95). He is currently a member of the Executive Committee of IUTOX (2013-2016). Dr. Wallace is co-Editor of the journal Toxicology and has served on scientific advisory panels to the NIEHS, NHLBI, the U.S. EPA and the U.S. FDA, including the Food Safety Advisory Committee. He is also a member of the Medical Expert Panel for the Vaccine Injury Compensation Program of the HHS. Dr. Wallace is a veteran with the ILSI organization as he has served as a scientific advisor to both the Risk Science Institute (1997-98) and the Health and Environmental Sciences Institute (1998-current).
2015-2016 HESI Executive Committee and Officers*

President (Term expires at close of 2017 Annual Meeting)  Dr. Timothy Pastoor (private)
Vice President (Term expires at close of 2017 Annual Meeting)  Dr. Lois Lehman-McKeeman (private)
Past-President (Term expires at close of 2016 Annual Meeting)  Dr. Laurie Hanson (private)
Chair (Term expires at close of 2016 Annual Meeting)  Prof. Herman Autrup (public)
Vice-Chair (Term expires at close of 2016 Annual Meeting)  Dr. Ernie Harpur (public)
Secretary (Term expires at close of 2016 Annual Meeting)  Dr. Charlene McQueen (public)
Treasurer (Term expires at close of 2016 Annual Meeting)  Dr. Serrine Lau (public)
Member-at-Large (Term expires at close of 2016 Annual Meeting)  Dr. Brian Berridge (private)
Member-at-Large (Term expires at close of 2016 Annual Meeting)  Dr. Peggy Guzzie-Peck (private)
Member-at-Large (Term expires at close of 2016 Annual Meeting)  Dr. Martin Philbert (public)

2015 HESI Representatives to the ILSI Board of Trustees

Representative (Term expires at close of 2016 Annual Meeting)  Dr. Alan Boobis (public)**
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Ken Wallace (public)
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Scott Belanger (private)**
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Samuel Cohen (public)**
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Dennis Devlin (private)**
Representative (Term expires at close of 2016 Annual Meeting)  Dr. Lewis Smith (public)**

*To be approved by HESI Board on June 9, 2015

**Elected/re-elected by ILSI AOM on January 2015
NOMINATIONS TO THE
2015-2016 HESI EMERGING ISSUES COMMITTEE

Four positions on the HESI Emerging Issues Committee (EIC) become vacant at the conclusion of the 2015 Annual Meeting. Nominations were solicited for the following positions: a private sector Vice Chair (from among existing EIC Science Advisors), two public sector Science Advisors and one private sector Science Advisors. At its February 2015 meeting, and in its capacity as nominating committee, the EIC prioritized the list of candidates and recommends the following slate of nominees:

Vice Chair:
Dr. Daniel A. Goldstein, Monsanto Company (one-year term)

Public Sector Science Advisors:
Dr. Toshihisa Ishikawa, NGO Personalized Medicine & Healthcare (re-nomination, three-year term)
Dr. Paul Lioy, Rutgers Environmental and Occupational Health Sciences Institute (three-year term)

Private Sector Science Advisors:
Dr. Kun Don Yi, Syngenta Crop Protection, Inc. (three-year term)
Goldstein, Daniel A., MD

Daniel Goldstein received a BS (Molecular Biology) from University of Wisconsin (1976) and an MD from Johns Hopkins (1981), followed by residency in Pediatrics (Johns Hopkins) and fellowship in Clinical Pharmacology and Medical Toxicology (University of Toronto). He is board certified by the American Boards of Pediatrics, Medical Toxicology, and Clinical Pharmacology, and by the Royal College of Physicians of Canada (Pediatrics). He is a fellow of the American Academy of Pediatrics and American College of Medical Toxicology. Following 10 years in clinical and consulting private practice in Denver, he joined Monsanto in 1998, was appointed Senior Science Fellow in 2002, and currently serves as Lead, Medical Sciences and Outreach, Monsanto Regulatory Affairs. He is involved in plant biotechnology, pesticide, and children’s health issues and has served on the EPA Child Health Protection Advisory Committee and the EPA Science Advisory Board (early-life exposure to carcinogens), as an advisor to the NAFTA Commission for Environmental Cooperation (child health indicators), and as a Leadership Counsel member, Biomonitoring Working Group member, and Chair of the Chemical Use and Exposure Pathways Sub-Group for the National Conversation on Public Health and Chemicals in the Environment. Dr. Goldstein has previously served on the Board of Directors of the American College of Medical Toxicology, and currently serves as a Science Advisor to ILSI/HESI (International Life Sciences Institute/Health and Environmental Sciences Institute), as a member of the Medical Toxicology Foundation Advisory Board, and as American Board of Pediatrics representative and Chair (2013-14) of the Conjoint Medical Toxicology Sub-Board, the examining and certification body for Medical Toxicology.
Yi, Kun Don (Sue), PhD  
Dr. Sue Yi is a senior toxicologist for Syngenta Crop Protection, LLC in the department of toxicology and health sciences. She received her B.S. in chemistry and biology at Texas Christian University and her M.S. in cardiovascular physiology and Ph.D. in pharmacology and neuroscience at the University of North Texas Health Science Center. Prior to joining Syngenta, Dr. Yi was a research assistant professor at the University of North Texas Health Science Center with a focus on understanding the mechanisms of estrogen mediated neuroprotection as well as examining race and gender disparities in health outcomes. She continues to hold an adjunct professorship at the university. Since joining Syngenta, Dr. Yi has been responsible for mode of action research for new and existing products, specifically focusing on endocrine and neuroendocrine research. She is the lead Syngenta toxicologist for endocrine related issues and serves on the advisory board of the Endocrine Policy Forum. She also focuses on developing industry-academic partnerships, including organizing the scientific session on endocrine disruptors at the International Workshop in Neuroendocrinology (Brazil 2013 and Argentina 2015).
Lioy, Paul J., PhD

He is a Professor and Vice Chair, Department of Environmental and Occupational Medicine at Rutgers Robert Wood Johnson Medical School (RWJMS), Piscataway, N.J. He is also Deputy Director for Government Relations at the Rutgers Environmental and Occupational Health Sciences Institute (EOHSI) and is the Director the Institute's program in Exposure Science. These are all part of the new Rutgers Biomedical Health Sciences (RBHS) Division of Rutgers: The State University. Dr. Lioy received the International Society of Exposure Science (ISES) Jerome Wesolowski Award for Lifetime Achievement in Exposure in 1998, and in 2003 he was the recipient of the Frank Chambers Award for lifetime achievement in Air Pollution from the Air and Waste Management Association. In 2006 he received the RWJMS R. Walter Schlesinger Basic Science award for Mentoring, and in 2008 he was named the Rutgers University Graduate School Distinguished Alumnus in Mathematics, Engineering and Physical Sciences, that same year he was named Distinguished Lecturer by the ISES. In 2009 he received a Conservation Award and the Ellen Harlin Walworth National medal for Patriotism from the Daughters of the American Revolution. In 2012 he received a community service award from the combined entities of the State of NJ, Union County and the Township of Cranford, NJ and the Chamber of Commerce. He has been a member of the Science Advisory Board (SAB) of the US EPA, and has been involved with multiple committees that dealt with air pollution standards, hazardous materials, as well as cost benefit analyses of Clean Air Act. Dr. Lioy was a member of the National Academy of Sciences Board of Toxicology and Environmental Studies, and was Chair of the National Research Council’s first committee on Exposure Assessment, and was recently the Vice Chair of its Committee on Exposure Science in the 21st Century. In addition he has been a member of 12 other committees that completed reports on hazardous wastes, air pollution (e.g. ozone and particulate matter), and human health. Dr. Lioy was a member of the US-Canada International Joint Commission Air Quality Advisory Board (1992-2007) that dealt with trans-boundary issues of Air Pollution and water pollution. He was Vice Chair of the EPA and CEQ WTC Expert Technical Panel (2004-2005). He was special councilor to the WHO on air pollution guidelines. He is a member of the International Academy of Indoor Air Sciences, and is a Fellow of the Collegium Ramazzini, Carpi, Italy. He is a founder of International Society for Exposure Science and was President from 1993-94. He has been an academic councilor to the New Jersey Legislature. He was Chair of it clean Air Council, 1983-1984, and is currently a Member of the Science Advisory Board of the NJ Department of Environmental Protection. Dr. Lioy was Co-Chair of the Preparedness College of the Office of Homeland Security and Preparedness of State of NJ. He is on the Executive Committee of the University Center on Disaster Preparedness and Emergency Response of RWJMS/Rutgers/ RWJ Hospital. Since 2012 he has been a member of committees, and is chairing one committee, that have dealt with the merger and now integration of the former university of Medicine and Dentistry of New Jersey (UMDNJ) into Rutgers University. Dr. Lioy has been an executive editor or associate editor of 7 journals that deal with environmental science, human exposure and/or air pollution. Currently, he is an Associate editor of the J. Environmental Health Perspectives, and Deputy Editor in Chief of the J. Exposure Science and Environmental Epidemiology. He has published over 290 peer reviewed papers, including results from scientific studies, reviews and vision on science and science policy, and ethics. He has also contributed book chapters, editorials, and has published five Books, including Dust: the Inside Story of its role in the September 11th Aftermath (Hardcopy/paperback) written for general audiences and a new book Titled Exposure Science. Since 2002 he has been identified by the Information Science Institute as one of the most cited scientists in the category of Environment/Ecology. Details Dr. Lioy’s accomplishments are listed in Wikipedia. His research has been funded for >35 years by numerous federal and state agencies, and other organizations on air pollution, exposure assessment, disasters, environmental health, and toxic materials. A major focus is on fundamental principles of Human Exposure Science, and their application to State, National and International Environmental Health problems. Included, are research on the Aftermath of the Attack on the WTC, the Toms River Cancer Cluster, Chromium exposure and health effects in Jersey City, NJ, Ozone and Asthma, Air Pollution in China, and nanoparticles in consumer products. He was part of the leadership of the NY/NNJ Consortium on the National Children’s Study that was funded for over seven years, and maintains a leadership role in the NIEHS supported Center for Environmental Exposure and Disease.
Dr. Toshihisa Ishikawa obtained the Ph.D. degree at the Graduate School of Science (Major: Biochemistry and Biophysics), Hokkaido University Japan in 1982. In the same year, he received a scholarship from the Deutscher Akademischer Austauschdienst (DAAD) and then moved to Germany. From 1982 till 1987, he was a postdoctoral fellow at the Institute of Physiological Chemistry (Prof. Helmut Sies) at the University of Düsseldorf Faculty of Medicine in Düsseldorf, West Germany. In April 1987, he returned to Japan to be appointed as Assistant Biochemist in the Department of Biochemistry, Medical School of Osaka University, Japan. In 1989, he went to Germany again to take the role of project leader in the Department of Tumor Biochemistry at the German Cancer Research Institute (DKFZ), Heidelberg. In 1991, Dr. Ishikawa left Germany for the USA, having been appointed as Assistant Professor in the Division of Pediatrics at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, U.S.A. In 1993, he received the Achievement Award of the International Life Sciences Institute. In December 1995, he was appointed Senior Scientist and Manager in the Department of Medicinal Biology at the Nagoya Central Research Laboratories of Pfizer, Inc., in Japan; and thereafter he became the Director of the Department of Research Technology Development at the Japanese Headquarters of Pfizer, Inc., in Tokyo, 1999. From 2000 till 2009, Dr. Ishikawa was Professor iat the Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Japan. In 2009, he moved to RIKEN Yokohama Institute to develop a rapid SNP detection method and to apply it to clinical pharmacogenomic research on human drug transporter genes. From 2012, he was also Professor (adjunct) at Yokohama City University Graduate School of Medicine, where he developed a platform of personalized medicine. In 2014, he founded NGO “Personalized Medicine & Healthcare” (President, Dr. Ishikawa). In addition Dr. Ishikawa has recently become Professor (adjunct) of Osaka Medical College, and he is directing a clinical research program of ALA-photodynamic therapy of brain tumor. Dr. Ishikawa was a member of the International Nomenclature Committee for Human ABC Transporter Genes. He directed the NEDO project entitled “International standardization of in-vitro functional assay methods for human drug transporters” (2005 - 2008). He then served as a member of the Steering Committee of the FDA Critical Path Transporter Workshop (2008). Presently, Dr. Ishikawa is a member of the Emerging Issues Steering Committee of the ILSI Health and Environmental Sciences Institute (Washington DC, USA) and the International Transporter Consortium (ITC). As the Chair, Dr. Ishikawa has recently organized the Gordon Research Conference on “Multi-Drug Efflux Systems” in Lucca, Italy, April 26-May 1, 2015.
HESI EMERGING ISSUES COMMITTEE
PROPOSED ROSTER

(June 2015 – June 2016)

LEADERSHIP (one-year term in each leadership position)
Chair: José E. Manautou, PhD, ATS, University of Connecticut (term expires June 2017)
Vice Chair: Daniel A. Goldstein, MD, Monsanto Company (term expires June 2018)**
Past Chair: Ruth A. Roberts, PhD, FBTS, ATS, ERT, FRCPATH, AstraZeneca R&D (term expires June 2016)

SCIENCE ADVISORS (public sector) (three-year terms)
Suzanne C. Fitzpatrick, PhD, DABT, US Food and Drug Administration (term expires June 2017)
Timothy Gant, PhD, CRCE, Public Health England (term expires June 2017)
George Gray, PhD, George Washington University (term expires June 2017)
Ronald N. Hines, PhD, US Environmental Protection Agency (term expires June 2017)
Toshihisa Ishikawa, PhD, NGO Personalized Medicine & Healthcare (term expires June 2018)**
James E. Klaunig, PhD, ATS, Indiana University (term expires June 2016)
Paul J. Lioy, Ph.D., Rutgers Environmental and Occupational Health Sciences Institute (term expires June 2018)**
Derek C.G. Muir, PhD, Environment Canada (term expires June 2016)
Flavio A.D. Zambrone, MD, PhD, University of Taubaté / Planitox (term expires June 2016)

SCIENCE ADVISORS (private sector) (three-year terms)
Ann M. Blacker, PhD, DABT, Bayer CropScience (term expires June 2016)
Matthew S. Bogdanffy, PhD, DABT, ATS, Boehringer-Ingelheim (term expires June 2017)
Jon C. Cook, PhD, DABT, Pfizer, Inc. (term expires June 2017)
Andrew Glickman, PhD, Chevron Energy Technology Company (term expires June 2017)
Michael Graziano, PhD, DABT, Bristol-Myers Squibb (term expires June 2016)
Kathleen A. Shelton, PhD, DuPont Haskell Global Centers for Health and Environmental Sciences (term expires June 2016)
Sue Yi, PhD, Syngenta Ltd. (term expires June 2018)**

EX OFFICIO MEMBERS (2014-2015 Leadership, HESI Board Program Strategy and Stewardship Committee)
Timothy Pastoor, PhD, DABT, Syngenta Ltd.
Ernie S. Harpur, BSc, PhD, ATS, FBTS, Newcastle University

**Elected/Re-Elected by HESI EIC